Twist Bioscience (TWST) Scheduled to Post Earnings on Thursday

Twist Bioscience (NASDAQ:TWSTGet Rating) will be releasing its earnings data after the market closes on Thursday, May 5th. Analysts expect Twist Bioscience to post earnings of ($1.26) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Twist Bioscience (NASDAQ:TWSTGet Rating) last released its earnings results on Friday, February 4th. The company reported ($0.91) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.08) by $0.17. Twist Bioscience had a negative return on equity of 27.10% and a negative net margin of 112.70%. The business had revenue of $42.00 million for the quarter, compared to analysts’ expectations of $38.22 million. During the same quarter in the prior year, the firm earned ($0.72) earnings per share. The firm’s revenue was up 48.9% on a year-over-year basis. On average, analysts expect Twist Bioscience to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

NASDAQ TWST opened at $30.22 on Thursday. The company has a 50-day simple moving average of $46.80 and a two-hundred day simple moving average of $72.66. Twist Bioscience has a 12-month low of $30.15 and a 12-month high of $144.14. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -9.02 and a beta of 0.89.

In other Twist Bioscience news, Director Jan Johannessen sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 16th. The shares were sold at an average price of $59.20, for a total value of $296,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James M. Thorburn sold 6,620 shares of the firm’s stock in a transaction dated Thursday, April 14th. The stock was sold at an average price of $42.85, for a total transaction of $283,667.00. Following the completion of the sale, the chief financial officer now owns 46,688 shares of the company’s stock, valued at $2,000,580.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,149 shares of company stock valued at $1,132,104. 3.10% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC purchased a new stake in Twist Bioscience in the fourth quarter worth about $39,000. Virtu Financial LLC purchased a new stake in Twist Bioscience in the fourth quarter worth about $436,000. Squarepoint Ops LLC lifted its holdings in Twist Bioscience by 186.5% in the fourth quarter. Squarepoint Ops LLC now owns 8,337 shares of the company’s stock worth $645,000 after buying an additional 5,427 shares during the period. LPL Financial LLC lifted its holdings in Twist Bioscience by 396.7% in the fourth quarter. LPL Financial LLC now owns 10,128 shares of the company’s stock worth $784,000 after buying an additional 8,089 shares during the period. Finally, UBS Group AG lifted its holdings in Twist Bioscience by 311.8% in the third quarter. UBS Group AG now owns 20,195 shares of the company’s stock worth $2,160,000 after buying an additional 15,291 shares during the period. Institutional investors and hedge funds own 98.81% of the company’s stock.

Several analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Twist Bioscience from a “sell” rating to a “hold” rating in a research report on Thursday, March 10th. The Goldman Sachs Group cut their price target on shares of Twist Bioscience from $105.00 to $55.00 and set a “neutral” rating for the company in a research report on Wednesday, April 13th. Robert W. Baird cut their price target on shares of Twist Bioscience from $113.00 to $70.00 in a research report on Monday, February 7th. Barclays cut their price target on shares of Twist Bioscience from $75.00 to $60.00 in a research report on Wednesday, April 20th. Finally, SVB Leerink dropped their target price on shares of Twist Bioscience from $110.00 to $70.00 and set a “market perform” rating for the company in a report on Monday, February 7th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $63.75.

About Twist Bioscience (Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

See Also

Earnings History for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.